US Patent

US11541035 — Oral formulations of metronidazole and methods of treating an infection using same

Formulation · Assigned to Appili Therapeutics Inc · Expires 2039-10-04 · 13y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects oral pharmaceutical compositions containing metronidazole and magnesium aluminum silicate, used to treat infections.

USPTO Abstract

The present disclosure provides oral pharmaceutical compositions comprising: 1) metronidazole or a pharmaceutically acceptable salt thereof; and magnesium aluminum silicate; or 2) metronidazole or a pharmaceutically acceptable salt thereof; magnesium aluminum silicate; and a flavoring agent. Methods of treating infection utilizing the oral pharmaceutical compositions are also provided.

Drugs covered by this patent

Metro I.V. In Plastic Container (METRONIDAZOLE) · Baxter

Patent Metadata

Patent number: US11541035
Jurisdiction: US
Classification: Formulation
Expires: 2039-10-04
Drug substance claim: No
Drug product claim: Yes
Assignee: Appili Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.